Shilpa Medicare Ka Dhoom! 🚀 Company ne Report kiya Record Revenue & EBITDA, Share Price Badhega Kya?

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorIshaan Verma|Published at:
Shilpa Medicare Ka Dhoom! 🚀 Company ne Report kiya Record Revenue & EBITDA, Share Price Badhega Kya?
Overview

Arre yaar, Shilpa Medicare ne kamaal kar diya! Is baar company ne 3rd quarter mein apna sabse high-ever quarterly revenue **₹411 crore** register kiya hai, jo pichhle saal se **28%** zyaada hai. Aur toh aur, EBITDA bhi record **₹115 crore** par pahunch gaya, matlab **40%** ka jump! Maza aa gaya!

Financial Results mein Toofani Tezi!

Shilpa Medicare ke liye December tak chalne wala quarter (3Q FY26) aur poore 9 mahine (9M FY26) financial terms mein next level rahe hain. Sirf 3rd quarter mein company ka revenue ₹411 crore tak pahunch gaya, jo 28% saal-dar-saal growth dikhata hai. Aur EBITDA toh ₹115 crore par pahunch kar 40% saal-dar-saal badh gaya. Iska matlab hai ki company ki profitability bhi increase hui hai, jiska dikhawa EBITDA margins mein 200 basis points ke sudhaar se hua hai, ab yeh 28% ho gaya hai.

Agar 9 mahine ki baat karein, toh revenue 14% badhkar ₹1,110 crore ho gaya hai, aur EBITDA 26% badhkar ₹323 crore ho gaya hai. Yahan bhi margins mein 300 basis points ka zabardast sudhaar dekha gaya hai, jo ab 29% par hai. Sabse acchi baat yeh hai ki Adjusted PAT 128% jump karke ₹146 crore ho gaya hai.

Growth Ke Peeche Ka Raaz Kya Hai?

Iss zabardast performance ke peeche kuch bade reasons hain. Sabse pehle, company ka Formulations business ne kamaal kiya hai, jisme 50% YoY growth dekha gaya. European Union (EU) mein toh growth 100% se bhi upar chala gaya! Dusra bada reason hai unka naya drug, 'Noduca™', jo NAFLD (Non-alcoholic Fatty Liver Disease) ke liye India mein launch hua hai. Yeh first-in-class therapy hai aur iske liye company ne 3 bade pharma partners ke saath tie-up kiya hai.

Iske alawa, Active Pharmaceutical Ingredients (API) segment mein bhi expansion ka fayda mil raha hai, khaas kar non-oncology products ke liye. Company ne kuch regulatory milestones bhi achieve kiye hain, jaise Rotigotine ke liye EU approval aur India mein Ondansetron ER ke Phase 3 trials complete karna. Kai API programs US FDA approval ki taraf badh rahe hain, matlab future mein aur bhi products aane wale hain.

Aage Kya? Outlook Zabardast!

Shilpa Medicare khud keh raha hai ki FY27 unke liye 'significantly better' hone wala hai. Yeh confidence unke badhte capacity utilization aur naye products ke launch se aa raha hai. FY26 ke 9 mahine mein company ka gross block ₹2,087 crore tha, aur iska achha use hone se margin improve hoga. Company multiple new products launch karne ki planning kar rahi hai, jisme Formulations, CDMO, API aur Biologics sab shaamil hain. Orion Corporation ke saath unka Recombinant Human Albumin product bhi Europe mein launch hone wala hai. Agar execution sharp raha toh investors ko fayda ho sakta hai, lekin new launches aur market penetration mein risks toh hamesha rehte hain.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.